SO

Solventum Corporation

SOLVHealthcareNASDAQ

Medical Instruments & Supplies · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$8.32B
+0.9% YoY
Net Income
$1.56B
+224.8% YoY
EBITDA
$2.55B
+66.9% YoY
Free Cash Flow
$489.0M

Scan Results

Daily timeframe
8 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3CONFIRMED MACD Negative CrossoverHistogram -0.0082, negative momentum
RSI OverboughtRSI 75.5, above 70, stock may be overbought
Sep 2 RSI OverboughtRSI 76.0, above 70, stock may be overbought
About Solventum Corporation

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. Valued at $15.61B, SOLV is a large-cap name in its sector. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.

Where SOLV stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, SOLV finished 21.16% above its 150-day moving average ($75.85) and 19.00% above its 200-day moving average ($77.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is SOLV overbought or oversold?

At the September 3, 2026 close, SOLV's RSI(14) was 75.5, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$15.61B
P/E (TTM)11.21
Fwd P/E12.69
EPS$8.18
Beta0.69
52W Change+25.8%
ROE34.0%
Analysis

The company holds $403.0M in cash, though total debt stands at $5.30B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $489.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 34.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $8.13B (2022) to $8.32B (2025).

The relatively low beta of 0.69 suggests SOLV is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing SOLV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms